ARMUZZI, ALESSANDRO
 Distribuzione geografica
Continente #
NA - Nord America 4480
EU - Europa 1116
AF - Africa 70
AS - Asia 56
SA - Sud America 2
OC - Oceania 1
Totale 5725
Nazione #
US - Stati Uniti d'America 4465
FI - Finlandia 332
FR - Francia 209
NL - Olanda 119
IE - Irlanda 104
DE - Germania 95
BE - Belgio 89
GB - Regno Unito 73
NG - Nigeria 67
SE - Svezia 41
IT - Italia 24
CA - Canada 15
IL - Israele 11
SG - Singapore 9
TR - Turchia 8
JP - Giappone 7
HK - Hong Kong 6
IR - Iran 5
CN - Cina 4
RO - Romania 4
BG - Bulgaria 3
EG - Egitto 3
PL - Polonia 3
RU - Federazione Russa 3
AE - Emirati Arabi Uniti 2
AT - Austria 2
EE - Estonia 2
ES - Italia 2
IN - India 2
UA - Ucraina 2
AR - Argentina 1
AU - Australia 1
BN - Brunei Darussalam 1
BR - Brasile 1
CH - Svizzera 1
DK - Danimarca 1
IS - Islanda 1
LU - Lussemburgo 1
MK - Macedonia 1
NO - Norvegia 1
PT - Portogallo 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
TW - Taiwan 1
Totale 5725
Città #
Chandler 1801
Lawrence 391
Princeton 391
Helsinki 332
Paris 206
Wilmington 169
Amsterdam 119
Dublin 104
Brussels 88
London 70
Benin City 66
San Mateo 62
Ann Arbor 46
Leawood 26
Fairfield 18
Woodbridge 18
Frankfurt am Main 16
Hanover 15
Toronto 13
Berlin 10
Falkenstein 10
Boardman 8
Kocaeli 8
Norwalk 5
Santa Clara 5
Campobasso 4
Seattle 4
Singapore 4
Atlanta 3
Beijing 3
Cambridge 3
Hirakata 3
Miami 3
Sassari 3
Sofia 3
Tel Aviv 3
Ashburn 2
Cairo 2
Collegeville 2
Hadera 2
Milan 2
Ottawa 2
Redwood City 2
St Petersburg 2
Stockholm 2
Tallinn 2
Tokyo 2
Toulouse 2
Turin 2
Vienna 2
Warsaw 2
Assiut 1
Augusta 1
Bandar Seri Begawan 1
Belgrade 1
Bitola 1
Buenos Aires 1
Buffalo 1
Cary 1
Chicago 1
Clearwater 1
Copenhagen 1
Dalsjoefors 1
Delhi 1
Dubai 1
Genoa 1
Henderson 1
Houston 1
Keflavik 1
Kemerovo 1
Kyiv 1
La Canada Flintridge 1
Lagos 1
Las Vegas 1
Lisbon 1
Livorno 1
Luxembourg 1
Madrid 1
Manchester 1
Mesa 1
New Delhi 1
New Orleans 1
New York 1
Oslo 1
Pamplona 1
Potomac 1
Raleigh 1
Redmond 1
Rome 1
Salt Lake City 1
San Diego 1
San Jose 1
Somerville 1
São Paulo 1
Taipei 1
Trento 1
Uppsala 1
Xiamen 1
Zurich 1
Totale 4111
Nome #
A liophylized and inactivated colture of Lactobacillus acidophilus increases Helicobacter pylori eradication rate. 46
Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) 45
Adalimumab in active ulcerative colitis: A "real-life" observational study 42
Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease 41
Effectiveness of Mesalazine, Thiopurines and Tumour Necrosis Factor Antagonists in Preventing Post-Operative Crohn's Disease Recurrence in a Real-Life Setting 39
Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial 38
13C-Breath Tests in the study of microsomal liver function 37
Long-term Combination Therapy with Infliximab Plus Azathioprine Predicts Sustained Steroid-free Clinical Benefit in Steroid-dependent Ulcerative Colitis 36
Infliximab in Steroid-dependent Ulcerative Colitis: Effectiveness and Predictors of Clinical and Endoscopic Remission 35
Discontinuation of Infliximab in Patients With Ulcerative Colitis Is Associated With Increased Risk of Relapse: A Multinational Retrospective Cohort Study 34
FOXP3(+) T Regulatory Cell Modifications in Inflammatory Bowel Disease Patients Treated with Anti-TNF alpha Agents 34
13C-breath tests in the study of mitochondrial liver function 32
Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment 32
Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) 31
Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease. Sandborn WJ, Feagan BG, Loftus EV Jr, Peyrin-Biroulet L, Van Assche G, D'Haens G, Schreiber S, Colombel JF, Lewis JD, Ghosh S, Armuzzi A, Scherl E, Herfarth H, Vitale L, Mohamed MF, Othman AA, Zhou Q, Huang B, Thakkar RB, Pangan AL, Lacerda AP, Panes J 30
3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management 30
Use of corticosteroids and immunosuppressive drugs in inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease 29
H-pylori poliantibiotic resistant strains in dyspeptic patients not eradicated by two consecutive triple eradication regimens 28
Disease patterns in late-onset ulcerative colitis: Results from the " IG-IBD ""AGED study""" 28
Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: An IG-IBD study 27
The intercellular adhesion molecule-1 polymorphisms in IBD 26
Long-term scheduled therapy with infliximab in inflammatory bowel disease 26
Multidisciplinary Management of Spondyloarthritis-Related Immune-Mediated Inflammatory Disease 26
Are we choosing wisely for inflammatory bowel disease care? The IG-IBD choosing wisely campaign 26
The role of tumour necrosis factor in the pathogenesis of immune-mediated diseases 25
A transition clinic model for inflammatory bowel disease between two tertiary care centers: outcomes and predictive factors 25
A case of pyoderma gangrenosum with ulcerative colitis treated with combined approach: infliximab and surgery 25
The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar 25
Use of biosimilars in inflammatory bowel disease: Statements of the Italian Group for Inflammatory Bowel Disease 25
Successful induction of clinical response and remission with certolizumab pegol in Crohn's disease patients refractory or intolerant to infliximab: a real-life multicenter experience of compassionate use 25
HELICOBACTER-PYLORI GASTRITIS WITH CYTOTOXIN ASSOCIATED PROTEIN ANTIBODIES (CAGA) - A COMPUTER-AIDED EVALUATION OF INFLAMMATORY CELL INFILTRATION IN THE LAMINA PROPRIA, ATROPHIC GASTRITIS AND ACQUIRED MALT 24
Helicobacter pylori-related diseases 24
Serum triiodothyronine-to-thyroxine (T3/T4) ratio predicts therapeutic outcome to biological therapies in elderly IBD patients 24
Higher vs Standard Adalimumab Induction Dosing Regimens and Two Maintenance Strategies: Randomized SERENE CD Trial Results 24
Gender affects 13C-ketoisocaproic breath test for liver mitochondrial function 23
Aminopyrine and methacetin 13C-breath tests to assess hepatic function in HCV-related chronic liver disease 23
Infliximab in Steroid-Dependent Ulcerative Colitis 23
anti-TNF agents as therapeutic choice in immune-mediated inflammatory diseases: focus on adalimumab 23
Adherence to international guidelines for the management of Helicobacter pylori infection among gastroenterologists and gastroenterology fellows in Italy: A Survey of the Italian Federation of Digestive Diseases - FISMAD 23
A machine-learning parsimonious multivariable predictive model of mortality risk in patients with Covid-19 22
Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders 22
Long-Term Scheduled Therapy with Infliximab in Inflammatory Bowel Disease 22
Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: an open-label pilot study 22
Update on the management of inflammatory bowel disease: specific role of adalimumab 22
Indicators of suboptimal tumor necrosis factor antagonist therapy in inflammatory bowel disease 22
Efficacy and safety of tofacitinib dose de-escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open 22
The PROSIT-BIO Cohort of the IG-IBD: A Prospective Observational Study of Patients With Inflammatory Bowel Disease Treated With Infliximab BioSimilars 22
Deep Remission at 1 Year Prevents Progression of Early Crohn's Disease 22
INFLAMMATORY BOWEL DISEASE (IBD) PATIENTS ON ANTI TNF-ALPHA THERAPY: RESPONSE TO THE INFLUENZA A/H1N1 VACCINE 21
Editorial: withdrawal of anti TNF-alpha - are we ready for biological therapy cycling? 21
Lipid Profiles in Patients With Ulcerative Colitis Receiving Tofacitinib-Implications for Cardiovascular Risk and Patient Management 21
COMPLEX PERIANAL FISTULIZING CROHN'S DISEASE: LONG-TERM EFFICACY OF COMBINED SETON PLACEMENT AND ANTI TNF-ALPHA AGENTS ALONE OR ASSOCIATED WITH IMMUNOSUPPRESSANTS 21
Oxygen free radical production in rat liver: Effect of different doses of ethanol on anoxia-reperfusion injury 21
Higher vs Standard Adalimumab Induction and Maintenance Dosing Regimens for Treatment of Ulcerative Colitis: SERENE UC Trial Results 21
Objective comparison of vedolizumab and ustekinumab effectiveness in Crohn's disease patients failure to TNF-alpha inhibitors 21
Helicobacter pylori eradication ameliorates migraine: An extended follow up study 21
Anti-CagA antibodies are associated with atrophic gastritis in a population at high gastric cancer risk: a morphometric study by computerized image analysis 21
Direct and Indirect Impact of COVID-19 for Patients with Immune-Mediated Inflammatory Diseases: A Retrospective Cohort Study 21
A lyophilized and inactivated culture of Lactobacillus acidophilus increases Helicobacter pylori eradication rates 21
Reply to Dr. Kotze's and Dr. Yamamoto's letter 21
Acute pancreatitis and parathyroid carcinoma: a case report and literature review 21
Efficacy of a multistep strategy for Helicobacter pylori eradication 21
Adalimumab in the treatment of immune-mediated diseases 21
Activity of Crohn's disease and small bowel contract-enhanced ultrasound findings 21
The genetic prediction of the clinical response to infliximab in Crohn's disease (CD): A role for polymorphisms in the TNFa and LTA genes? 20
H-pylori gastric infection and rheumatic diseases 20
Therapeutic drug monitoring with vedolizumab in inflammatory bowel disease 20
Drug-Related Pneumonitis in Patients Receiving Vedolizumab Therapy for Inflammatory Bowel Disease 20
Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IG-IBD technical review based on the GRADE methodology 20
Personalized Clinical Phenotyping through Systems Medicine and Artificial Intelligence 20
Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor-α agents 20
Study of liver function in healthy elderly subjects using the C-13-methacetin breath test 20
Novel Topics in Inflammatory Bowel Disease 20
IBD: Infliximab dose optimization in IBD-proactive or reactive? 20
Reply to Dr. Joob et al.'s letter 20
Glucose disposal in morbidly obese patients in the early post-operative period 20
Can C-13 urea breath test predict resistance to therapy in Helicobacter pylori infection? 20
Letter: SARS-CoV-2 infection in two IBD patients treated with dual targeted therapy 20
The awareness of the IBD nurse position among patients from an Italian tertiary IBD centre 20
Dual Targeted Therapy in Patient With Extensive Crohn's Disease: Different Response at Distinct Location 20
Review article: breath testing for human liver function assessment 20
Aminopyrine and methacetin breath tests in HCV-related chronic liver disease 20
Achievement of sustained deep remission with adalimumab in a patient with both refractory ulcerative colitis and seronegative erosive rheumatoid arthritis 20
Risk factor analysis for therapy related adverse events and infections in elder patients with Inflammatory Bowel Disease; An analysis from the IG-IBD aged study 20
Haplotypic analysis of heat shock protein 70 (HSP70) single nucleotide polymorphisms (SNPs) in susceptibility and phenotype of inflammatory bowel disease (IBD) 19
Cancer Risk in Inflammatory Bowel Disease: A 6-Year Prospective Multicenter Nested Case-Control IG-IBD Study 19
Young GI angle: Should I go abroad? 19
Six-day or seven-day regimens with ranitidine bismuth citrate plus high-dose clarithromycin and tinidazole are both effective against Helicobacter pylori infection 19
Clinical management of rheumatologic conditions co-occurring with inflammatory bowel diseases 19
Anti TNF-α therapy for ulcerative colitis: current status and prospects for the future 19
Importance of changes in epithelial cell turnover during Helicobacter pylori infection in gastric carcinogenesis 19
New concepts concerning management of Helicobacter pylori infection: 2 years after the Maastricht Consensus Report 19
Diet and Nutrients in Gastrointestinal Chronic Diseases 19
COVID-19 Vaccination Willingness and Hesitancy in Patients With Inflammatory Bowel Diseases: Analysis of Determinants in a National Survey of the Italian IBD Patients' Association 19
The management of inflammatory bowel diseases in the era of COVID-19 pandemic: When "non-urgent" does not mean "deferrable" 19
Activities related to inflammatory bowel disease management during and after the coronavirus disease 2019 lockdown in Italy: How to maintain standards of care 19
Management of difficult-to-treat patients with ulcerative colitis: focus on adalimumab 19
Role of HMGB1 as a suitable biomarker of subclinical intestinal inflammation and mucosal healing in patients with inflammatory bowel disease 19
Insulin-dependent diabetes mellitus affects eradication rate of Helicobacter pylori infection 19
3-day antibiotic therapy with azithromycin and tinidazole plus lansoprazole or pantoprazole to cure H-pylori infection 19
Totale 2397
Categoria #
all - tutte 38269
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 38269


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20208 0000 00 00 0008
2020/2021309 1304 0102 3920 6940130
2021/2022217 421140 30 724 17184843
2022/20235216 84455425569 431546 20546 9734653420
Totale 5750